Zhou H, et al. - In this meta-analysis of 10 studies with 1,371 participants, researchers evaluated the diagnostic ability of microRNA-21 (miR-21) and microRNA-30c (miR-30c) for prostate cancer (PCa). These studies were identified from databases of PubMed, Embase, and Web of Knowledge on September 6, 2018. They estimated the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under curve (AUC) of the summary receiver-operating characteristic (SROC) curve with the corresponding 95% CI by using Stata 12.0 and Meta-Disc 1.4. The pooled SEN was 0.91 and SPE was 0.88 for miR-21, with a pooled PLR and NLR, respectively, of 7.74 and 0.1. The DOR was 77.64 and AUC of SROC was 0.95. The pooled SEN was 0.74 and SPE was 0.78 for miR-30c, with pooled PLR 3.39 and NLR 0.34. For miR-30c, the DOR was 10.06 and AUC of SROC was 0.83. A good performance of miR-21 and a moderate performance of miR-30c was reported in PCa.